Medical XpressCholine Supplementation in Young Children with Fetal Alcohol Spectrum Disorder Can Have Durable Developmental Benefits

⚠️ Long-Term Follow-Up of Small Randomized Cohort

Fetal alcohol spectrum disorder (FASD) affects an estimated 1% to 5% of the global population and remains associated with significant cognitive, behavioral, and developmental challenges. Therapeutic options are limited, and few interventions have been evaluated through randomized controlled trials. Investigators conducted a five-year follow-up of children previously enrolled in three randomized placebo-controlled studies of choline supplementation administered between ages 2 and 5 years. The analysis evaluated whether short-term nutritional intervention could produce durable neurodevelopmental benefits later in childhood.

Clinical Considerations

• The original randomized trials enrolled 104 children with FASD, with 84 completing treatment and 58 participating in the long-term follow-up assessment.
• Children received nine months of choline supplementation or placebo during early childhood.
• At approximately age 9 years, children who had received choline demonstrated 7% higher nonverbal IQ scores than controls.
• Working-memory scores were approximately 9% higher among children previously treated with choline, with reported medium-to-large effect sizes.
• Higher choline exposure appeared associated with greater cognitive benefit, suggesting a potential dose-response relationship.
• No significant differences were observed in parent-rated behavioral measures or several broader cognitive outcomes evaluated during follow-up.

Practice Applications

• Recognize that choline remains one of the few biological interventions evaluated through randomized controlled trials in children with FASD.
• Interpret these findings as promising but preliminary because long-term follow-up involved a relatively small cohort.
• Consider emerging nutritional and neurodevelopmental research when counseling families affected by prenatal alcohol exposure.
• Avoid assuming immediate post-treatment outcomes fully capture intervention benefits, as some cognitive gains emerged only during later follow-up.
• Monitor future studies designed to clarify optimal timing, duration, and dosing of choline supplementation.